Therapeutic Drug Monitoring (TDM) & Managing Narrow Therapeutic Index (NTI) Drugs
Narrow therapeutic index drugs require precise serum concentration assays paired with Bayesian dosing algorithms to prevent catastrophic toxicity while ensuring clinical efficacy.
Pharmacological Mechanism & Kinetic Schema
The Steady-State Equilibrium Principle
Upon repeated dosing at constant intervals (tau), drug accumulation occurs until the rate of elimination matches the rate of administration. True steady-state is achieved strictly after 4 to 5 elimination half-lives (t1/2). Serum blood draws executed before steady-state attainment yield dangerously misleading pharmacokinetic interpretations.
Vancomycin AUC/MIC Guided Monitoring
Consensus clinical guidelines have shifted from isolated trough monitoring (15–20 mg/L) to 24-hour area-under-the-curve over minimum inhibitory concentration (AUC24/MIC) targets of 400 to 600 mg·h/L. This approach maximizes bactericidal killing against MRSA while dramatically reducing the incidence of acute kidney injury (AKI).
Aminoglycoside Extended-Interval (Once-Daily) Dosing
Exploiting concentration-dependent bactericidal killing (Cmax/MIC >= 8–10) and the post-antibiotic effect (PAE), consolidated single-dose regimens achieve high therapeutic bactericidal spikes while allowing extended washout periods where trough levels drop below 1 mg/L, preventing saturable endocytic uptake into renal proximal tubular cells.
Clinical Pharmacologist & Biochemist · Specialist in Pharmacokinetics & Hospital Pharmacotherapy · Published on June 20, 2007 at 02:05
